Your Cart Item
Reports Within

Parameters

Reports Within:

Parameter Include:

Requisites
Measures

Number of red blood cells in the blood

Identifies

Red blood cell disorders

Measures: Number of red blood cells in the blood

Identifies: Red blood cell disorders

60
Mins

Homes

1M
Happy

Customers

4.9
Google

Rating

Certified

Labs

What is the maximum days the report can be obtained for the test

The report for the test ALL Risk Stratification Gene Panel- T-ALL can be obtained within 10-14 business days from the date of sample receipt.

What are the prerequisites for the test ALL Risk Stratification Gene Panel- T-ALL

  • Patients with a confirmed diagnosis of T-cell acute lymphoblastic leukemia (T-ALL)
  • Specimen type: Bone marrow or peripheral blood
  • Specimen volume: 3 mL bone marrow or 5 mL peripheral blood
  • Specimen container: Lavender top (EDTA) tube or yellow top (ACD) tube
  • Specimen stability: Stable at room temperature for up to 48 hours
  • Rejection criteria: Clotted or hemolyzed specimens

What are the measure values for the test ALL Risk Stratification Gene Panel- T-ALL

  1. CEBPA
  2. CTNNB1
  3. DNMT3A
  4. ETV6
  5. EZH2
  6. FLT3
  7. IL7R
  8. JAK1
  9. JAK2
  10. KMT2A
  11. NOTCH1
  12. NRAS
  13. PHF6
  14. PICALM
  15. PTEN
  16. PTPN11
  17. RAS
  18. RUNX1
  19. SETD2
  20. STIL-TAL1
  21. WT1

What does this test ALL Risk Stratification Gene Panel- T-ALL identify?

ALL Risk Stratification Gene Panel- T-ALL

This test is designed to identify genetic mutations and abnormalities in patients with T-cell Acute Lymphoblastic Leukemia (T-ALL). T-ALL is a subtype of acute lymphoblastic leukemia that primarily affects T-cell lymphocytes. The test analyzes a panel of genes associated with T-ALL to determine the risk stratification and prognosis of the disease.

The identification of specific genetic mutations can help in tailoring treatment strategies and predicting the response to therapy. This test can provide valuable information for clinicians to make informed decisions regarding the management of T-ALL patients.

Why is this test ALL Risk Stratification Gene Panel- T-ALL taken?

The ALL Risk Stratification Gene Panel- T-ALL test is taken to help determine the risk stratification of patients with T-cell acute lymphoblastic leukemia (T-ALL). This test analyzes the genetic profile of the patient to identify specific genetic abnormalities that may affect the prognosis and treatment options for T-ALL.

By identifying genetic mutations and abnormalities, healthcare providers can better tailor treatment plans for patients with T-ALL, leading to more personalized and effective care. The results of this test can help guide decisions about treatment options, including targeted therapies and clinical trials.

No FAQs available.

Customer Google Rating